scholarly journals Intracranial delivery of synthetic mRNA to suppress glioblastoma

Author(s):  
Hao Peng ◽  
Xingrong Guo ◽  
Jinjuan He ◽  
Chao Duan ◽  
Minghuan Yang ◽  
...  
Keyword(s):  
2018 ◽  
Vol 7 (12) ◽  
pp. 2737-2741 ◽  
Author(s):  
Gourab Chatterjee ◽  
Yuan-Jyue Chen ◽  
Georg Seelig

2018 ◽  
Vol 202 (2) ◽  
pp. 608-617 ◽  
Author(s):  
Yitian Xu ◽  
Lu Huang ◽  
Jonathan L. Kirschman ◽  
Daryll A. Vanover ◽  
Pooja M. Tiwari ◽  
...  

Life ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. 1192
Author(s):  
Hideyuki Nakanishi

Synthetic mRNAs, which are produced by in vitro transcription, have been recently attracting attention because they can express any transgenes without the risk of insertional mutagenesis. Although current synthetic mRNA medicine is not designed for spatiotemporal or cell-selective regulation, many preclinical studies have developed the systems for the translational regulation of synthetic mRNAs. Such translational regulation systems will cope with high efficacy and low adverse effects by producing the appropriate amount of therapeutic proteins, depending on the context. Protein-based regulation is one of the most promising approaches for the translational regulation of synthetic mRNAs. As synthetic mRNAs can encode not only output proteins but also regulator proteins, all components of protein-based regulation systems can be delivered as synthetic mRNAs. In addition, in the protein-based regulation systems, the output protein can be utilized as the input for the subsequent regulation to construct multi-layered gene circuits, which enable complex and sophisticated regulation. In this review, I introduce what types of proteins have been used for translational regulation, how to combine them, and how to design effective gene circuits.


Development ◽  
1995 ◽  
Vol 121 (3) ◽  
pp. 721-730 ◽  
Author(s):  
S.E. Witta ◽  
V.R. Agarwal ◽  
S.M. Sato

XIPOU 2, a member of the class III POU domain family, is expressed initially in Spemann's organizer, and later, in discrete regions of the developing nervous system in Xenopus laevis. XIPOU 2 may act downstream from initial neural induction events, since it is activated by the neural inducer, noggin. To determine if XIPOU 2 participates in the early events of neurogenesis, synthetic mRNA was microinjected into specific blastomeres of the 32-cell stage embryo. Misexpression of XIPOU 2 in the epidermis causes a direct switch in cell fate from an epidermal to a neuronal phenotype. In the absence of mesoderm induction, XIPOU 2 has the ability to induce a neuronal phenotype in uncommitted ectoderm. These data demonstrate the potential of XIPOU 2 to act as a master regulator of neurogenesis.


Sign in / Sign up

Export Citation Format

Share Document